Animal Models of Neurological Disorders

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 241-244

  Chesselet, Marie Francoise ^a   Carmichael, S Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; SUPEROXIDE DISMUTASE;

ADDICTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; BRAIN SIZE; CAENORHABDITIS ELEGANS; CELL DEATH; DIABETIC NEUROPATHY; EDITORIAL; EMOTIONAL DISORDER; EPILEPSY; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; MACHADO JOSEPH DISEASE; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SPINAL CORD INJURY; WHITE MATTER;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; NERVOUS SYSTEM DISEASES; ORGAN SIZE; SPECIES SPECIFICITY;

EID: 84859731838     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0118-9     Document Type: Editorial

References (28)

1. Carmichael ST. Animal models of stroke: size, mechanism and purpose. NeuroRx 2005; 2: 396-409.
2. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behaviour. Nat Rev Neurosci 2009; 10: 861-872.
3. Dunnett SB, Lelos M. Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease. Prog Brain Res 2010; 184: 35-51.
4. Chesselet M-F, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn Mice. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0104-2 (in this issue).
5. Limb GA, Martin KR. Sixth ARVO/Pfizer Ophthalmics Research Institute Conference Working Group. Current prospects in optic nerve protection and regeneration: sixth ARVO/Pfizer Ophthalmics Research Institute conference. Invest Ophthalmol Vis Sci 2011;; 52: 5941-5954.
6. Wood MD, Kemp SW, Weber C, Borschel GH, Gordon T. Outcome measures of peripheral nerve regeneration. Ann Anat 2011; 193: 321-333.
7. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-477.
8. Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010; 8: e1000344.
9. Scott S, Kranz JE, Cole J, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008; 9: 4-15.
10. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007; 26: 1-13.
11. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6: 1045-1053.
12. Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008; 39: 2824-2829.
13. Lohle M, Reichmann H. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci 2010; 289: 104-114.
14. Auvin S, Pineda E, Shin D, Gressens P, Mazarati A. Novel Animal Models of Pediatric Epilepsy. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0119-8 (in this issue).
15. Höke A. Animal Models of Peripheral Neuropathies. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0116-y (in this issue).
16. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
17. Ehrlich ME. Huntington's Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0112-2 (in this issue).
18. Dürr A, Stevanin G, Cancel G, Duyckaerts C, Abbas N, Didierjean O, Chneiweiss H, Benomar A, Lyon-Caen O, Julien J, Serdaru M, Penet C, Agid Y, Brice A. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996; 39: 490-499.
19. Colomer Gould VF. Mouse Models of Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease). Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0117-x (in this issue).
20. Fremont R, Khodakhah K. Alternative Approaches to Modeling Hereditary Dystonias. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0113-1 (in this issue).
21. Bubier JA, Chesler EJ. Accelerating Discovery for Complex Neurological and Behavioral Disorders through Systems Genetics and Integrative Genomics in the Laboratory Mouse. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0111-3 (in this issue).
22. Courtine G, Bunge MB, Fawcett JW, et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans? Nat Med 2007; 13: 561-566.
23. Zhang K, Sejnowski TJ. A universal scaling law between gray matter and white matter of cerebral cortex. Proc Natl Acad Sci U S A 2000; 97: 5621-5626.
24. Back SA, Riddle A, Dean J, Hohimer AR. The Instrumented Fetal Sheep as a Model of Cerebral White Matter Injury in the Premature Infant. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0108-y (in this issue).
25. Cook DJ, Tymianski M. Nonhuman Primate Models of Stroke for Translational Neuroprotection Research. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0115-z (in this issue).
26. Rosenzweig ES, Courtine G, Jindrich DL, et al. Extensive spontaneous plasticity of corticospinal projections after primate spinal cord injury. Nat Neurosci 2010; 13: 1505-1510.
27. Rosenzweig ES, Brock JH, Culbertson MD, et al. Extensive spinal decussation and bilateral termination of cervical corticospinal projections in rhesus monkeys. J Comp Neurol 2009; 513: 151-63.
28. Nout YS, Rosenzweig ES, Brock JH, Strand SC, Moseanko R, Hawbecker S, Zdunowski S, Nielson JL, Roy RR, Courtine G, Ferguson AR, Edgerton VR, Beattie MS, Bresnahan JC, Tuszynski MH. Animal Models of Neurologic Disorders: A NonhumanPrimate Model of Spinal Cord Injury. Neurotherapeutics 2012. doi: 10. 1007/s13311-012-0114-0 (in this issue).